PAIN THERAPEUTICS WKN: A2PGL8 ISIN: US14817C1071 Kürzel: SAVA Forum: Aktien Thema: Hauptdiskussion

https://www.cassavasciences.com/financial-information/sec-filings

Sind 2. Millionen... aber das ist ein sehr gutes Zeichen!

Insiderkauf von 100.000 Aktien durch Sanford Robertson

Der Director hat für ne gute Million Dollar Shares gekauft 😎👍🏼

Was ist denn jetzt los? Weiß einer etwas?

Kannst du bitte kurz zusammenfassen was das Dokument aussagt?

https://www.cassavasciences.com/node/15986/html

We expect to announce top-line data results of our open-label study approximately year-end 2022.

Gute Zwischenergebnisse und rot 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️

Fast wieder bei 20€ gelandet 🥹

Wahrscheinlich einfach nur Algos die kicken

Gibts einen Grund für den Anstieg?🧐

Sieht doch ganz gut aus :^)

Allgemeine Marktsituation, USA-Taiwan-China Spannung etc.

Gestern Rakete und heute wieder Abflug? Ich habe keine NEWS gefunden - null. Weiß einer was?

CASSAVA SCIENCES, INC. 4,081,633 Shares of Common Stock We are offering 4,081,633 shares of our common stock at a price of $49.00 per share to certain institutional and accredited investors pursuant to this prospectus supplement and the accompanying base prospectus. Our common stock is listed on The Nasdaq Stock Market, or Nasdaq, under the symbol “SAVA.” On February 9, 2021, the closing price of our common stock was $57.56 per share. Recently, the trading price of our common stock has increased significantly, which we believe is attributable to the positive results we announced in connection with an interim analysis from an open-label study of simufilam, our lead drug candidate for the treatment of Alzheimer’s disease. On December 31, 2020, the last reported sale price of our common stock was $6.82 per share, as compared to $57.56, which was the last reported sale price on February 9, 2021. The intra-day price of our common stock had a high and low on February 4, 2021 of $117.54 and $63.01, respectively. There is a potential for rapid and substantial decreases in the price of our common stock, including decreases unrelated to our operating performance or prospects, which may cause you to lose some or all of your investment.